A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Conditions
Advanced Cancer · Advanced Solid Tumor · Melanoma · Metastasis · Pleural Mesothelioma · Renal Cell Carcinoma · MSI-High · Mismatch Repair Deficiency · Colorectal Cancer · Hepatocellular Carcinoma · Hepatocellular Cancer · Renal Cell Cancer · Kidney Cancer · Skin Cancer · Non Small Cell Lung Cancer · NSCLC · Anaplastic Lymphoma Kinase Genomic Tumor Aberrations · ALK Genomic Tumor Aberrations
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Colorado Cancer Center, Aurora, Colorado, United States
Contact: Study coordinator (Kathy P Clinical Research Coordinator IV) · melanomaclinicalresearch@olucdenver.onmicrosoft.com · 303.724.9815Contact: Principal Investigator (Sapna Patel, MD)Florida Cancer Specialists, Lake Mary, Florida, United States
Dartmouth Hitchcock, Lebanon, New Hampshire, United States
Contact: Principal Investigator (Konstantin H Dragnev, MD)Brown University Health Cancer Institute, Providence, Rhode Island, United States
Contact: Study coordinator (Cancer Institutre Clinical Research Nurse) · research@brownhealth.org · 312-583-8700MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Apostolia-Maria Tsimberidou, MD, PhD)
Study leads
Lionel Lewis, MA, MB.Bch, MD
Study Chair
7 Hills Pharma